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BACKGROUND: Sevoflurane can be used as sedative-analgesic drug with endothelial
protective properties. We tested whether low-dose sevoflurane inhalation provides
sustained inhibition of detrimental granulocyte-platelet aggregation in humans.
METHODS: Ten healthy male volunteers were enrolled in this crossover study. Each
subject inhaled sevoflurane for 1 h at 0.5–1 vol % end-tidal concentration in oxygen (50
vol %). Inhaling oxygen (50 vol %) alone served as control. Venous blood samples were
collected at baseline before inhalation, immediately after inhalation, and 24 h thereaf-
ter, and were used for flow cytometry to determine platelet surface marker (CD41,
CD42b, CD62P/P-selectin, and PAC-1) on platelets and granulocytes and for kaolin-
induced clot formation, as assessed by thromboelastography. In flow cytometry
experiments, platelets were stimulated with arachidonic acid (AA, 30 M), adenosine
diphosphate (ADP, 1 M), and thrombin receptor agonist peptide-6 (TRAP-6, 6 M).
RESULTS: AA, ADP, and TRAP-6 markedly increased the expression of CD62P on
platelets, whereas CD42b (shedding) and PAC-1 (heterotypic conjugates) expres-
sion decreased. The amount of granulocyte-platelet aggregates increased upon
agonist stimulation. Low-dose sevoflurane inhalation reduced ADP-induced
CD62P expression on platelets 24 h after inhalation, and inhibited the formation of
granulocyte-platelet aggregates under stimulation with AA and ADP after 1 and
24 h, and with TRAP-6 after 24 h compared with control. Inhibition of granulocyte-
platelet aggregates was accompanied by reduced clot firmness 24 h after sevoflu-
rane inhalation compared with control.
CONCLUSIONS: We demonstrated for the first time that inhaling low-dose sevoflu-
rane (1 vol % end-tidal) inhibits agonist-induced granulocyte-platelet interactions
24 h after administration and thus counteracts thromboinflammatory processes.
(Anesth Analg 2008;106:1749–58)
An increasing body of evidence supports the potent
anti-ischemic properties of halogenated ethers in pa-
tients undergoing coronary artery bypass graft sur-
gery.1–3 The protection is thought to be due to the
preconditioning-mimicking effects by this class of
drugs.4,5 Our group previously demonstrated that inhal-
ing low-dose sevoflurane protects the endothelium
against reperfusion injury in a human forearm ischemia
model.3 We further showed in healthy volunteers that
sevoflurane inhalation at subanesthetic concentrations
modifies the human blood transcriptome and decreases
the expression of proinflammatory L-selectin (CD62L)
on granulocytes for up to 48 h,6 consistent with the
occurrence of a “second window of protection.” Thus,
sevoflurane, with its pleasant nonpungent odor, might
serve to provide conscious sedation combined with
organ protection in all clinical settings in which ischemia–
reperfusion plays a role.
In contrast to these promising findings, which
would suggest the use of low-dose sevoflurane inha-
lation as a valuable alternative to IV propofol sedation in
cardiovascular at-risk patients, are reports on enhanced
expression of platelet markers and increased formation
of granulocyte-platelet aggregates by sevoflurane imply-
ing procoagulant effects.7 Conversely, severe inhibition
of platelet function8,9 and prolonged bleeding times in
patients undergoing sevoflurane anesthesia were also
shown.10 Another study found no inhibition of human
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platelet aggregation induced by thrombin.11 In view of
these conflicting findings obtained from studies with
collected human blood exposed in vitro to the anes-
thetic gas, or from studies in patients undergoing
surgery with sevoflurane anesthesia, we sought to
determine the effects of sedative doses of sevoflu-
rane (1 vol % end-tidal) on platelet marker expres-
sion and function under well-controlled conditions
using a crossover volunteer study.
Preconditioning was shown to enhance arterial
patency in patients with preinfarction angina4,12,13 and
in sevoflurane-treated patients undergoing coronary
artery bypass graft surgery.14 In an in vivo dog model,
intermittent coronary artery ligation before test ischemia
was capable of enhancing arterial patency by selectively
inhibiting procoagulant granulocyte-platelet aggregation.15
Therefore, we hypothesized that inhaling sevoflurane
would mimic ischemic preconditioning and attenuate
platelet-mediated thrombosis by reducing the molecular
indices of agonist-induced granulocyte-platelet aggrega-
tion. Because stimulation of several surface receptors is
required for full platelet activation,16 we studied inducible
activation of several keyplatelet receptors using a variety of
platelet agonists, including the P2Y12 receptor agonist
adenosine diphosphate (ADP), the thromboxane A2 pre-
cursor arachidonic acid (AA) targeting the thromboxane
A2 receptor, and the thrombin receptor agonist peptide-6
(TRAP-6) targeting the thrombin receptor. Finally, since
sevoflurane continues to exert its actions long after its
physical clearance from the human body,6 and postopera-
tive thromboembolic complications typically occur within
the first 24 h after surgery,17 we also evaluated the late
effects of low-dose sevoflurane inhalation on platelets and
heterotypic aggregation 24 h after administration.
METHODS
Subjects
The study was approved by the local ethics com-
mittee and all subjects gave written informed consent.
The research was performed in accordance with the
Declaration of Helsinki (2000). Clinicaltrials (www.
clinicaltrials.gov) registration number isNCT00526695. Ten
healthy male Caucasian volunteers participated in the
study. All subjects were nonsmokers, and refrained
from drinks and food containing caffeine and dark
chocolate for 24 h. Participants fasted overnight and 20
mg of prophylactic esomeprazole was administered.
Study Protocols
In this study with crossover design, each partici-
pant underwent the same protocol with and without
sevoflurane (Fig. 1A). Participants were randomly
allocated to the protocols, which were at least 4 days
apart (time between two inhalation periods). Experi-
ments were performed in temperature-controlled
(25°C) and quiet rooms. An IV line was placed into a
large cubital or forearm vein, and 50 mL 0.9% NaCl
solution was infused during inhalation. Prophylactic
ondansetron against nausea and vomiting (0.5 mg)
was given IV. In the protocol with sevoflurane inha-
lation, sevoflurane in 50 vol % oxygen was inhaled for
1 h by the spontaneously breathing volunteers using a
tight facemask connected to the common gas outlet of
an anesthesia machine (Siemens Servo 900D ventila-
tor; Siemens Life Support Systems, Sona, Sweden) to
achieve an end-tidal concentration of 1.0 vol %.3,6
Control experiments consisted of 50 vol % oxygen
inhalation for 1 h. Noninvasive arterial blood pres-
sure, oxygen saturation, electrocardiogram, end-tidal
carbon dioxide and sevoflurane concentrations (Drae-
ger Infinity Delta XL, Draeger Medical Systems, Dan-
vers, MA), and Bispectral Index (A2000 monitor ®
with three adhesive electrodes to the forehead, single
channel: Fp1-Fpz, version 3.3; Aspect Medical Sys-
tems, Inc., Norwood, MA) were recorded. Blood
samples were taken from the IV line at indicated time
points without the use of a tourniquet (Fig. 1A).
Determination of Platelet Surface Markers and
Granulocyte-Platelet Aggregates Using Flow Cytometry
After collection, heparinized blood samples were
immediately processed for flow cytometry. The
expression of surface markers was determined at
baseline, immediately after 1 h of sevoflurane or
oxygen-control inhalation, and 24 h later in all 10
volunteers. Because stimulation of several surface
receptors is required for full platelet activation,16 we
studied inducible activation of several key platelet
receptors using a variety of platelet agonists. One
milliliter aliquots of the collected whole blood were
exposed to medium alone (unstimulated), AA (pre-
cursor of thromboxane A2 targeting the thrombox-
ane A2 receptor, 30 M, Sigma Chemicals, St. Louis,
MO), ADP (targeting the P2Y12 receptor, 1 M,
Sigma Chemicals), or to TRAP-6 (targeting the
thrombin receptor, 6 M, Bachem, Heidelberg, Ger-
many) ex vivo for 10 min. Preliminary experiments
showed that these agonist concentrations elicited a
strong and highly reproducible response of platelet
markers, as previously reported.9 Subsequently, 50
L of stimulated blood was incubated in the dark
with 3 L of the primary fluorochrome-labeled
antibody in endotoxin-free tubes for 10 min at room
temperature. Erythrocytes were lysed by addition of
lysis buffer (450 L) (Becton Dickinson, San Jose´,
CA) for an additional 20 min at room temperature in
the dark. The lysates were fixed for 30 min in 500 L
0.2% paraformaldehyde solution at room tempera-
ture in the dark. The samples were centrifuged, and
the cell pellets were resuspended in 0.5 mL of
phosphate-buffered saline supplemented with 2%
FCS (pH 7.2) and stored at 4°C in the dark until flow
cytometric measurements. The FACS Calibur (Becton
Dickinson) flow cytometer was used to measure
R-phycoerythrin (PE)-fluorescence at 580 nm and FITC-
fluorescence at 515 nm. Cells were distinguished from
each other by typical physical characteristics, resulting in
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well-delineated cellular subpopulations that are easily
identified on forward (cell size) and side-scatter (granu-
larity) plots. Furthermore, granulocytes and platelets
were identified by use of monoclonal antibodies against
cell-specific antigens. To determine expression levels of
surface markers on platelets and granulocyte-platelet
aggregates, mean fluorescence intensities (MFI) of platelet
markers weremeasured in the predefined gates containing
the cellular subgroups of interest. The MFI of platelet
markers in the granulocyte gate directly indicate the forma-
tion of granulocyte-platelet aggregates (Fig. 1B). The fol-
lowing surface markers were used: P-selectin (CD62P,
PE-labeled, clone AK-4, Santa Cruz Biotechnology, CA),
CD41a (GP IIb/IIIa, PE-labeled, clone HIP8, BD Bio-
sciences, San Jose´, CA), CD41b (GP IIb of IIb/IIIa, PE-
labeled, Santa Cruz Biotechnology, CA), CD42b (GPIb,
clone AN51, FITC-labeled, DAKO, Glostrup Denmark),
PAC-1 (epitope of the activated CD41a, FITC-labeled,
Becton-Dickinson), and the marker for polymorpho-
nuclear granulocytes CD15 (PE-labeled, clone 80H5,
Immunotech, Marseille, France). The fluorescence sig-
nals from unstained samples and samples treated with
isotype-matched antibodies (PE-labeled IgG, eBio-
science, Wembley, UK, and FITC-labeled IgG, Becton
Dickinson) were used for correction and subtracted
from the signals obtained in samples exposed to true
antibodies. A minimum of 20,000 events was counted
on each sample, and recorded data were analyzed
using CellQuest Software (Becton Dickinson). All data
are shown as MFI or percent change of MFI from the
respective baseline values.
Thromboelastography
Thromboelastographic (TEG) measurements were
also determined at baseline, 1 h after sevoflurane
inhalation, and 24 h later in control and sevoflurane-
treated blood samples. Quality control procedures
were performed before each measurement, and pro-
cedures for TEG analysis were done according to the
Figure 1. Panel A: Study protocols. Participants inhaled sevoflurane (SEVO) for 60 min at 0.5–1.0 vol % end-tidal
concentration. Blood samples for flow cytometry and thromboelastography were collected before and immediately after
sevoflurane inhalation, and 24 h thereafter. Inhalation of 50 vol % oxygen served as control (CTL). Panel B: Whole blood flow
cytometric analysis of granulocyte-platelet aggregates in the absence (native) and presence of thrombin receptor agonist
peptide-6 (TRAP-6) activation (6 M). Granulocytes were identified by their characteristic light scatter properties (forward
scatter FSC and side scatter SSC) and the binding of CD15-specific antibodies (not shown). Fluorescence intensity (FL2) of
platelet-specific markers such as P-selectin (CD62P) measured in the granulocyte gate R1 was used as surrogate for
granulocyte-platelet aggregate formation. Please note the shift in fluorescence intensity after TRAP-6 stimulation, indicating
formation of granulocyte-platelet aggregates.
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manufacturer’s descriptions (TEG Hemostasis Ana-
lyzer, Hemoscope Corporation, Niles, IL). Three mil-
liliters of blood was gently collected through the IV
cannula into a 5-mL syringe and discarded. Subse-
quently, 9 mL of blood was drawn into a 10-mL
syringe fromwhich 5 mL was immediately transferred
to a citrate-(3.8%) containing tube. The tube was
gently mixed, and TEG analysis was performed 1 h
later.18 One milliliter of citrated blood was transferred
into a kaolin vial and mixed. Subsequently, 340 L
was transferred into prewarmed cups containing 20
L of 0.2 M CaCl2 and carefully mixed. From the
recorded signals, four parameters of clot formation
were measured including the reaction time (R-time
corresponds to the distance measured from the begin-
ning of the trace to the point where 2 mm of diver-
gence is detected), K-time (time from start of tracing to
20 mm divergence), MA (maximum amplitude indi-
cates maximal divergence of the tracing lines and clot
firmness the components of which are fibrin and
platelet interactions), and  angle (measured from the
tracing slope over the time indicating rate of clot
formation) were determined. G-modulus, which indi-
cates normalized shear elastic modulus, was calcu-
lated as follows G  100  MA/(100  MA). Please
note that G-modulus increases exponentially in pro-
portion to MA, and thus is more indicative of small
changes in clot strength.
Statistical Analysis
Data are given as mean  sd. The Kolmogorov–
Smirnov test was used to test for normality of the under-
lying data distribution. Paired t-tests or Wilcoxon’s signed
rank test were used for comparisons between sevoflu-
rane and control samples depending on the underly-
ing distribution. P  0.05 was considered significant.
Analyses were performed using SigmaStat Version 2
(SPSS Science, Chicago, IL).
RESULTS
Table 1 shows the measured blood cell counts and
fibrinogen levels, which were within normal limits in
the 10 healthy volunteers. All subjects could be
aroused on tactile stimulation, and tolerated the pro-
cedures well, except for one who experienced tran-
sient nausea. None of them experienced an excitement
phase during sedation (Table 2).
Expression of Surface Markers on Platelets After
Stimulation with AA, ADP, and TRAP-6
We first determined the effects of the three different
platelet activators AA, ADP, and TRAP-6 on platelet
surface markers including P-selectin (CD62P), GP
IIb/IIIa (CD41a and GD41b representing different
epitopes of the same protein), GPIb (CD42b), and PAC-1
(activated CD41) in blood samples of the untreated
volunteers. Although CD41a exhibited increased expres-
sion, as measured by theMFI, upon AA and TRAP-6 but
not ADP stimulation, CD41b, a different CD41 epitope,
only showed increased expression after strong TRAP-6
stimulation (Supplementary Figures S1A–B, available at
www.anesthesia-analgesia.org). In contrast, CD42b ex-
pression was reduced after stimulation, most probably
due to shedding of this surface marker (Supplementary
Figure S1C, available at www.anesthesia-analgesia.org),
as previously reported.19 P-selectin (CD62P) exhibited a
graded increase in expression in response to AA, ADP,
and TRAP-6 activation (Supplementary Figure S1D,
available at www.anesthesia-analgesia.org), whereas
PAC-1 was reduced after strong stimulation with ADP
and TRAP-6, probably due to formation of platelet-
derived microparticles or adhesion to granulocytes
(see next paragraph), but unaffected after AA stimu-
lation (Supplementary Figure S1E, available at www.
anesthesia-analgesia.org).
Formation of Granulocyte-Platelet Aggregates After
Stimulation with AA, ADP, and TRAP-6
To determine the formation of heterotypic
granulocyte-platelet aggregates, we measured the
MFI of the various platelet markers in the pre-
defined granulocytes (CD15-positive cells) contain-
ing gate (Fig. 1B). There was a significant increase in
Table 1. Volunteer Characteristics
Age
(yr)
BMI
(kg/m2)
Hemoglobin
(g/dL)
Leukocytes
(103/L)
Platelets
(103/L)
Fibrinogen
(g/L)
32.3 6.2 23.6 1.5 14.6  0.9 5.0  1.3 223  32 2.5  0.4
Data are mean SD.
BMI  body mass index (kg/m2).
Table 2. Recorded Vital Signs and BIS Values
Baseline
30 min after
initiation of inhalation
CTL
SBP (mm Hg) 117 8 112 8
HR (bpm) 62 9 57 10
RR (min1) 13  2 14 2
Spo2 (%) 97  2 99 1
BIS 95  5 93 4
SEVO
SBP (mm Hg) 117 6 115 8
HR (bpm) 67 7 61 7
RR (min1) 14  2 15 3
Spo2 (%) 98  1 98 1
ET(SEVO) (vol %) — 0.8 0.2
BIS 96  2 72 7*
Data are mean SD.
CTL  inhalation of 50 vol % oxygen; SEVO  sevoflurane 0.5–1 vol % in 50 vol % oxygen;
ET(SEVO)  end-tidal sevoflurane concentration; SBP  systolic blood pressure; HR  heart
rate (in beats per minute or bpm); RR respiratory rate (breaths per minute), SpO2 oxygen
saturation (finger tip); BIS  bispectral index.
* P  0.05 vs baseline.
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CD41a and CD42b expression upon AA, ADP, and
TRAP-6 stimulation on the granulocyte surface,
whereas P-selectin (CD62P) and PAC-1 were only
increased after strong stimulation with ADP and
TRAP-6 (Supplementary Figure S2A–E, available at
www.anesthesia-analgesia.org). Of note, although
CD42b expression on platelets decreased after
stimulation (shedding), a significant increase in
CD42b expression on granulocytes was observed
indicating a marked formation of granulocyte-
platelet aggregates. Together, these experiments in-
dicate significant granulocyte-platelet aggregation
after stimulation in the blood of the untreated study
subjects.
Delayed Beneficial Effects of Low-Dose Sevoflurane
Inhalation on ADP-Induced P-Selectin (CD62P)
Expression and Granulocyte-Platelet Aggregation
To reduce interindividual variability and to minimize
possible confounding variables, the effects of sevoflu-
rane on platelet marker expression and granulocyte-
platelet aggregate formation were determined in a study
with healthy volunteers using a crossover design. The
effects of sevoflurane were evaluated at two time points:
immediately after 1 h of low-dose sevoflurane inhalation
and 24 h later. Differences in control and sevoflurane
protocols were expressed as percent changes in MFI for
the various markers from baseline. Although all platelet
markers were unaffected after 1 h of inhalation (Figs.
2A–H), ADP-induced P-selectin expression on platelets
was significantly reduced 24 h later (P  0.02). Signifi-
cant reduction in granulocyte-platelet aggregation was
detected after sevoflurane treatment, occurring uponAA
and ADP stimulation immediately after inhalation
(Figs. 3A–D). This effect was even more pronounced
24 h later and also observed in native unstimulated
as well as TRAP-6-activated blood samples (Figs.
3E–H). Together, these experiments show that seda-
tive doses of sevoflurane administered for only 1 h
effectively inhibit agonist-induced granulocyte-
platelet aggregation 24 h after administration.
Low-Dose Sevoflurane Inhalation Maintains Normal
Coagulation but Counteracts Procoagulant Actions 24
Hours Later
To test whether sevoflurane-induced changes in
platelet surface markers would further affect clot
formation, we used TEG. Measurements were per-
formed at baseline, after 1 h of inhalation, and 24 h
later. No changes in R-time, K-time, and  angle
were observed in blood samples of sevoflurane-
treated volunteers immediately after treatment com-
pared to untreated controls (Fig. 4). In contrast, MA
and even more G-modulus were increased in the
control Group 24 h later, which was reversed by
administration of sevoflurane. These results provide
evidence that low-dose sevoflurane inhalation
maintains normal hemostasis, but exerts late antico-
agulant activity by counteracting hypercoagulation.
DISCUSSION
Using the well-controlled conditions of a crossover
volunteer study, we were able to show that brief low-
dose sevoflurane inhalation decreased ADP-induced
P-selectin (CD62P) expression on platelets, effectively
inhibited agonist-induced granulocyte-platelet aggrega-
tion, and further attenuated thrombus formation, as
assessed by TEG 24 h after administration. Our findings
are important because of the following reasons.
First, previous human in vivo studies evaluating
sevoflurane effects on platelet function and aggre-
gation did not investigate the effects at lower seda-
tive doses.8,20 Second, no studies determined the
late effects of sevoflurane on platelet function and
coagulation, i.e., 1 day after the clearance of sevoflurane
from the human body. A single study reported some
residual effects of sevoflurane on platelets 1 hour after
inhalation.20 We now provide evidence that sevoflurane
blunts the responsiveness of platelets, and exerts a
strong delayed effect on granulocyte-platelet aggre-
gation after stimulation with multiple physiological
activators, which is consistent with the concept of an
“anticoagulant preconditioning.” Analogous to an-
esthetic preconditioning of the heart, in which the
myocardium is rendered more resistant to poten-
tially lethal ischemia,5,21 granulocyte-platelet inter-
action was attenuated in response to thrombotic
stimulation after sevoflurane pretreatment, representing
different aspects of the same biological process termed
“preconditioning.” Since leukocyte-platelet interactions
are of particular relevance in the pathogenesis of inflam-
mation and thrombosis,16 the observed delayed actions
on platelet aggregation at subanesthetic concentrations
may be beneficial in many clinical settings such as the
postoperative period in which a hypercoagulable state is
occurring.17
Using flow cytometry for the determination of the
key platelet surface markers CD41a, its activated form
PAC-1, CD42b, and P-selectin (CD62P) in the presence
and absence of AA, ADP, and TRAP-6 activation, we
were able to track the effects of sevoflurane on
platelet markers and heterotypic aggregation.22 The
combined use of TEG, further allowed us to test
whether the observed changes in markers affected
clot formation. TEG, which is sensitive to all of the
interacting cellular and plasma components, moni-
tors shear elasticity of a whole blood sample, and
was successfully used in the assessment of postop-
erative hypercoagulation.23
Platelet activation initiates arterial thrombosis, con-
tributes to inflammation, and participates in host
defense, cancer cell metastasis, and wound healing.24
In our study, we were able to confirm previously
described CD42b shedding upon platelet activation.19
Reduced PAC-1 expression in the platelet gate after
stimulation was also detected and may have been due
to adherence of activated platelets to granulocytes, as
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evidenced by the increased PAC-1 signal in the granu-
locyte gate. Alternatively, this might have been due to
agonist-induced formation of platelet-derived micro-
particles.25 Aggregation of platelets to leukocytes is
predominantly P-selectin-dependent and mediated by
binding to the counterligand PSGL-1 (CD162) on
leukocytes.26,27 Binding of CD11a/18 to ICAM-2 and
CD11b/18 to CD42b (via fibrin) further enhance this
interaction, but play a less important role. Platelets
bound to leukocytes markedly enhance adhesion to
Figure 2. Platelet surface markers after sevoflurane administration. Differences in markers (CD41a, 41b, CD42b, CD62P, and
PAC-1) between sevoflurane (SEVO) versus control treatment (CTL) are expressed in percent change in mean fluorescence
intensity (MFI) from baseline. Panel A–D: after 1 h of sevoflurane inhalation (postinhalation). Panel E–H: 24 h after
sevoflurane inhalation. P values are given on the right side of each graph and are bold if statistically significant (P  0.05).
Data are mean  sd.
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the endothelium by “secondary capture.” Increased
formation of leukocyte-platelet aggregates was re-
ported in patients with stable and unstable angina,
acute myocardial infarction, and in patients undergo-
ing coronary artery interventions.28–30 In myocardial
infarction, leukocyte-platelet interaction at the site of
Figure 3. Granulocyte-platelet aggregation after sevoflurane administration. Please note that fluorescence intensities of
platelet-specific markers were determined in the granulocyte gate (see Fig. 1B). Differences in platelet markers (CD41a, 41b,
CD42b, CD62P, and PAC-1) between sevoflurane (SEVO) versus control treatment (CTL) are expressed in percent change in
mean fluorescence intensity (MFI) from baseline. Panel A–D: after 1 h of sevoflurane inhalation (postinhalation). Panel E–H:
24 h after sevoflurane inhalation. P values are given on the right side of each graph and are bold if statistically significant (P
0.05). Data are mean  sd.
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plaque rupture may represent an important mecha-
nism for inadequate reperfusion (“no-reflow” phe-
nomenon).31 In the perioperative setting, vascular
surgical patients with subsequent graft occlusion dem-
onstrated greater postoperative increases in circulat-
ing granulocyte-platelet aggregates compared with
patients with patent grafts.32 Interestingly, this study
also suggests that heterotypic aggregation may be a
more sensitive marker of platelet activation than platelet
surface markers themselves. Importantly, heterotypic
aggregates do not only reflect, but also effect, cardiovas-
cular disease.33 Increased production of reactive oxygen
species by platelet-activated leukocytes may destabilize
atherosclerotic plaques and modify cardiovascular
outcome.34,35 In a pig model, administration of
blocking recombinant PSGL-1-immunoglobulin, the
P-selectin counterligand, was shown to decrease
neointima formation after balloon injury and reste-
nosis within the stent.36 Hence, sustained reduction
in heterotypic aggregation after low-dose sevoflu-
rane inhalation, as observed in our study, suggests
strong antithromboinflammatory actions.
Previous reports of sevoflurane’s effects on platelet
function have been highly conflicting. Obviously, in
vitro conditions differ from in vivo conditions with
intact endothelium, present plasma proteins, no arti-
ficial cellular activation, and the intact rheologic envi-
ronment. Ex vivo in vitro studies found that even low
sevoflurane doses (0.5 MAC) transformed platelets
into more adhesive phenotypes.9,7 Enhanced forma-
tion of leukocyte-platelet aggregates and increased ex-
pression of P-selectin,7 especially in stimulated blood
samples, combined with seemingly paradoxical impair-
ment of clot formation,9 were also reported. In vivo,
however, Huang et al.37 reported reduced P-selectin
expression on platelets and reduced leukocyte-platelet
aggregation in unstimulated and ADP-stimulated blood
samples of sevoflurane-anesthetized patients (approxi-
mately 4 vol %). Sevoflurane also prolonged bleeding
times in patients,10 but this is not considered clinically
relevant.38 In our protocols with low-dose sevoflurane
inhalation, we only detected a slight delayed reduction
in clot strength compared with baseline. However, clot
strength was increased 24 h after oxygen inhalation in
control protocols, which was completely offset by
sevoflurane administration. The reason for this hyperco-
agulable state is not clear, but may have been related to
the reported procoagulant effects of oxygen on plate-
lets.39,40 Irrespectively, sevoflurane completely abolished
this untoward effect and reestablished normal coagula-
tion. Since maximal clot strength was reported to corre-
late with postoperative thrombotic complications, this
finding may be of clinical significance.23 Together, our
results confirm previous findings but further extend
these by showing strong late inhibitory effects of low-
dose sevoflurane on heterotypic aggregation and throm-
bus formation.
What are the possible mechanisms underlying the
inhibition of granulocyte-platelet aggregation by
sevoflurane? Based on our results, the following
explanations can be put forward. Suppression of
thromboxane A2 formation
41 and inhibition of cal-
cium mobilization in platelets42 were previously
shown, and may be involved primarily in the im-
mediate inhibitory effects of sevoflurane on hetero-
typic aggregation. However, delayed effects on
aggregates may rather depend on transcriptional
changes and changes in protein expression,6 consis-
tent with the concept of late preconditioning. Plate-
lets, although anucleate cells, do contain functional
mRNA,43 and upon activation or inhibition, were
shown to change their protein expression profile.44 Thus,
it may be speculated that an increase in adenosine
elicited by anesthetic gases21 might block the P2Y12
receptor for ADP on platelets and subsequently down-
regulate P-selectin expression (“clopidogrel-like” ef-
fect).45 Indeed, a reduction in ADP-induced P-selectin
expression by 40% as observed in our study (sevoflurane
vs control) is equivalent to the effects on P-selectin
after 7 days of clopidogrel therapy (300 mg loading
and 75 mg daily dose). Additional mediators, such as
nitric oxide and prostaglandins, might have further
modulated platelet function. Another possibility
would be that sevoflurane affects activation and ad-
hesion of leukocytes rather than platelets. In support
Figure 4. Clot strength, as determined by thromobelastography. Differences in maximum amplitude (MA, panel A) and
G-modulus (panel B) between sevoflurane (SEVO) versus control treatment (CTL) are expressed in percent change from
baseline. *P  0.05 vs. CTL. §P  0.05 vs respective baseline. Data are mean  sd.
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of this view, we recently demonstrated that sevoflu-
rane at subanesthetic concentrations induces tran-
scriptional changes and downregulates L-selectin
(CD62L) on granulocytes in humans 24–48 h later.6
Sedative doses of sevoflurane further decreased
CD11b expression after ischemia–reperfusion injury in
the human forearm.3 Hence, it can be postulated that
counterligands for platelet markers on granulocytes
such as PSGL-1 or ICAM-2 may be also decreased
after sevoflurane administration, a hypothesis which
needs to be confirmed in future studies.
STUDY LIMITATIONS AND SPECIFIC REMARKS
Our findings obtained in this well-controlled study
with healthy volunteers should be confirmed in the
clinical setting with patients suffering from multiple
comorbidities. In the current study, platelet-specific
markers measured in the granulocyte gate were used
for identifying granulocyte-platelet aggregates. Al-
though this is a well established method, which was
previously used,46 this approach does not allow a
one-by-one identification of granulocyte-platelet ag-
gregates, as would be possible in multicolor flow
cytometry, and thus measured MFI must rather be
considered surrogate markers for granulocyte-platelet
aggregate formation. Stimulation with AA, ADP, and
TRAP-6, as used in our study, only mimics part of the
changes present in endothelial injury. Future studies
should help to delineate all mechanisms underlying
inhibition of granulocyte-platelet aggregation by
sevoflurane and further determine whether higher
doses of sevoflurane would affect platelet function
and coagulation more profoundly. We used esome-
prazole to protect the participants from the potential
hazards of pulmonary aspiration, and ondansetron
was used to prevent nausea and vomiting. Although
no effects of these drugs on granulocyte-platelet ag-
gregation or clot formation were previously reported,
we cannot completely exclude any effects on blood
cells. Finally, TEG with citrated blood, as opposed to
native blood, was shown to have a trend toward
hypercoagulation, but these measurements can be still
used as reliable surrogates.18
In conclusion, in this human crossover study, we
demonstrate that inhaling sevoflurane at low subanes-
thetic doses inhibits agonist-induced detrimental
granulocyte-platelet aggregation 24 h after adminis-
tration and attenuates thrombus formation. Since
postoperative thromboembolic complications typi-
cally occur within the first 24 h after surgery, our
findings are of clinical significance. Our results further
suggest that conscious sedation with sevoflurane
could benefit patients at high thrombotic risk under-
going interventional procedures in cardiology or en-
dovascular procedures.
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